Brief: Clinuvel Pharmaceuticals Submitted Formal Application To European Medicines Agency
05/09/2022 02:29
Sept 5 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX :
* SUBMITTED FORMAL APPLICATION TO EUROPEAN MEDICINES AGENCY
TO
EXPAND APPROVED INDICATION FOR SCENESSE
* APPLICATION TO EXPAND APPROVED INDICATION FOR SCENESSE TO
INCLUDE TREATMENT OF ADOLESCENT EPP PATIENTS
Source text for Eikon: ID:nASX4ClGwv
Further company coverage: CUV.AX
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist